Market Signal Briefing

The ETH price prediction suddenly turned extremely bullish after Ether tested the $4,800 resistance level. These surges came after Bitcoin broke its previous ATH and briefly touched the $125,000 mark.

Ethereum has since failed at breaking that resistance, and fell down to a strong support level at $4.3K.

However, while Ethereum’s price jumps look impressive, it has limited potential to bring massive ROI compared to newer projects.If you’re hunting for the best altcoins that could multiply your investment 50X or 100X, presale tokens like Pepenode and Maxi Doge deserve your attention. 

Let’s see why Pepenode and Maxi Doge could be some of the best altcoins to buy right now.

Ethereum Pushes Toward $5K as Institutional Money Floods In
Ethereum is heating up in October with some serious institutional backing. ETH currently trades at $4,339, down slightly by 1.02% in the last 24 hours, with a market cap of $523.9 billion. 

Institutional investors poured $176.6 million into Ethereum ETFs in just one day on October 6, with BlackRock alone accounting for $92.6 million of that total. October has already seen $621.4 million in total ETF inflows, more than double what September brought in.

The supply situation is getting tight too. Exchange supply dropped to levels we haven’t seen since 2016 because institutions are pulling ETH off exchanges and holding it. Standard Chartered just bumped their 2025 ETH target up to $7,500, pointing out that treasury companies and ETFs have grabbed 3.8% of all ETH in circulation since June.

Right now, ETH has strong support around $4,300, and analysts think it could push to $4,700 or even $4,900 by mid-October if the buying keeps up. 

History shows Ethereum usually gains about 24% in Q4, and surges above $4,000, some analysts see a path to $7,000 or $8,000. Those ETH price prediction numbers look decent, but they’re nothing compared to what presale altcoins can deliver in the coming months.

Maxi Doge ($MAXI) – High-Risk Meme Coin That Lets You Trade With Massive Leverage
Maxi Doge is one of the best altcoins to buy now if you’re the type who likes taking massive risks for potentially massive rewards. This meme coin gives you access to 1000X leverage trading with zero stop-loss protection, which means a winning trade could explode your investment overnight. 

The flip side is just as extreme – one bad call and your position vanishes in seconds, so you really need to know what you’re doing before jumping in.

The whole vibe around Maxi Doge centers on its mascot character. Maxi the dog is basically that gym bro trader who lives for gains, both in the weight room and on the crypto charts. If you’re the kind of person who goes all-in and doesn’t play it safe, then $MAXI tokens might be exactly what you need.

The presale has pulled in close to $3 million so far and shows no signs of slowing down. Early buyers who grab $MAXI tokens now can stake them and earn 119% APY while they wait for the DEX listing. Head over to the official Maxi Doge website and lock in your tokens before the presale window closes in the coming weeks.

Pepenode ($PEPENODE) – Gaming Meets Crypto in This Earn-While-You-Play Token
Pepenode deserves a spot on any list of best altcoins because it has tangible real-world utility that most meme coins lack. Instead of waiting around for hype to drive prices up, you earn tokens by managing a virtual crypto mining game. The whole setup revolves around collecting and arranging different node types to maximize your reward output.

The mechanics aren’t complicated but they require some planning. Different nodes provide unique multipliers and benefits when you slot them into your setup. Smart players figure out the best combinations early and use their earned tokens to keep expanding their operations faster than everyone else.

Right now the presale raised around at $1.8 million raised and offers staking 722% APY returns. Those are the kind of numbers that don’t stick around once projects hit exchanges. Visit the Pepenode website and grab your first batch before the price explodes after listing.

Final Thoughts – Should You Chase Best Altcoins or Wait For ETH Price Predictions to Come True?
Ethereum’s push toward $5K is grabbing headlines right now, but the real money is being made elsewhere. ETH already sits at a $523 billion market cap, which means even a strong rally to $7,500 only gets you about 70% gains. 

Compare that to presale projects like Maxi Doge and Pepenode that could easily 10X or 20X from current prices once they hit exchanges.

Maxi Doge gives you extreme leverage opportunities that could multiply small positions into life-changing money. Pepenode lets you earn tokens just by playing their game while staking rewards sit above 700%. Both are still in presale, which means you’re getting the absolute lowest entry prices available.

These opportunities don’t last long once tokens go public. The gap between presale pricing and exchange listing prices is where the biggest profits happen. 

Visit the official Maxi Doge and Pepenode websites right now and lock in your position before these best altcoins explode and early investors cash out with massive profits.

This article contains information about a cryptocurrency presale. Crypto Economy is not associated with the project. As with any initiative within the crypto ecosystem, we encourage users to do their own research before participating, carefully considering both the potential and the risks involved. This content is for informational purposes only and does not constitute investment advice.

XRP’s attempt to sustain its ongoing recovery toward $3 is now in jeopardy, as its trajectory faces potential selling pressure following a massive on-chain transfer.

According to data from Whale Alert on October 13, a total of 23,880,253 XRP (worth approximately $62.64 million) was transferred from an unknown wallet to the Binance exchange.

Large transfers like this often indicate that whales may be preparing to sell, which can weigh on market sentiment and price stability. 

The move comes as XRP trades around $2.50, following a sharp drop triggered by the broader market crash on October 10.

The sudden spike in exchange inflows raises caution that selling activity could increase in the near term, possibly leading to a loss of the $2.50 support.

To gauge short-term performance, Finbold turned to OpenAI’s ChatGPT model, which projected that if profit-taking intensified, XRP could retreat toward $2.40 and $2.45, and sustained selling might push it down to $2.20. 

Conversely, if market demand absorbs the selling pressure, XRP could consolidate before attempting another move toward the $3 resistance.

XRP’s technical outlook
Meanwhile, pseudonymous analyst Mikybull noted that XRP is still displaying one of the most bullish setups in the crypto market as it consolidates below a key Fibonacci resistance after a strong multi-month rally. 

XRP price analysis chart.Source: Tradingview
On the monthly chart, XRP hovers near the 1.272 Fib level ($2.34), a potential breakout zone that could pave the way toward $6.26 and even $21.7 in the long term.

The chart also shows a bullish breakout from a multi-year downtrend, now retested as support around $1.38, suggesting a strong base. 

If momentum continues, XRP could be on the verge of a parabolic move, with Fibonacci projections pointing to triple-digit upside potential from current levels.

XRP price analysis 
At press time, XRP traded at $2.58, up 7% in the past 24 hours but still down 14% over the past week. 

XRP seven-day price chart. Source: Finbold
For now, the asset’s next move will likely depend on whether the broader crypto market maintains its recovery from the October 10 sell-off, a continuation of which could offset the recent whale-induced selling pressure.

Featured image via Shutterstock

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

A developer, "dori," has lauded the Maximal Extractable Value (MEV) innovation on the Cardano (ADA) blockchain. In a post on X, the developer praised Cardano’s eUTXO model and Ouroboros PoS for making protocol-level MEV almost impossible. This, the developer insists, is a better alternative to Ethereum’s design flaw.

Cardano's proof-against-MEV issuesFor context, MEV refers to the extra profit that the system makes when there is a reorder, insert or censor transaction during confirmation on the blockchain. This is done by miners or validators and sometimes by "MEV bots" scanning the network.

"dori" said this has created a situation where MEV bots make a profit by spotting a trade in the memepool and quickly place their own transaction before it is finalized. This allows them to make gains from the predictable price movement.

If a bank used its customers’ transaction data to profit off them, that would obviously be a problem. But in crypto, exploiting others’ transaction data for profit better known as MEV has become normalized and even turned into a business.

This screenshot shows MEV bots making… pic.twitter.com/19n8v5iABW

— dori (@dori_coin) October 13, 2025 According to the developer, ordinary users are losing a small amount of value each time they transact because bots or block producers manipulate the transaction.  

He insists that Cardano’s consensus mechanism is preferable to Ethereum’s as there is no global mempool for bots to scan. Rather, it is locally validated, so bots cannot reorder transactions for profit.

"dori" believes Cardano’s technical design is more aligned with decentralization and fairness. "Once you really understand how other layers work and then look at Cardano, you'll see just how efficient, secure, and well-designed it truly is," he stated.

What can Ethereum and competing chains do?In contrast, across Ethereum and other layers, efforts are on to mitigate MEV, but it remains a structural issue. "dori" insists that this structural issue makes it even more difficult to resolve.

Some users have also commended Cardano for sidestepping MEV, as it makes it more user-friendly than other chains.

Neo X blockchain, in its recent mainnet upgrade, has stepped up its ecosystem and made it MEV-protected. The chain stated the goal is to make the platform censorship-resistant and truly decentralized.

Michael Saylor’s company, Strategy Inc., has resumed its regular Bitcoin accumulation after pausing for a week. The purchase occurred during a volatile market phase when Bitcoin wiped out most of its monthly gains. 

Despite the turbulence, Strategy increased its Bitcoin holdings by 220 BTC for $27.1 million, paying an average of $123,561 per coin. The company now owns 640,250 BTC valued at $71.7 billion, with an average acquisition cost of $74,000 per Bitcoin. This move underscores the firm’s unwavering belief in Bitcoin as a long-term store of value.

Strategy’s Aggressive Accumulation ContinuesAccording to the issued press release, Strategy financed the latest acquisition by selling shares of STRF, STRD, and STRK, raising nearly $27.3 million in total. The breakdown included $19.8 million from STRF, $5.8 million from STRD, and $1.7 million from STRK sales. 

The firm’s Bitcoin portfolio has delivered a 25.9% yield year-to-date, reflecting the success of its accumulation strategy despite periodic downturns. Moreover, this purchase followed nine consecutive weeks of buying earlier this year, during which Strategy acquired over 21,000 BTC for $2.46 billion.

Besides, the purchase coincided with a major market correction triggered by new U.S. trade measures. Bitcoin fell sharply to $104,000 after President Donald Trump announced a 100% tariff on Chinese goods beginning November 1. Saylor’s renewed accumulation suggests he viewed the drop as a buying opportunity, reinforcing his reputation for counter-cyclical investment behavior.

Market Context and Broader SentimentSaylor hinted at the purchase yesterday, sharing a post celebrating Bitcoin’s resilience. The message reflected optimism despite the broader market’s decline. His timing aligns with his long-term approach accumulating Bitcoin during fear-driven sell-offs and maintaining conviction during corrections.

In parallel, Tether CEO Paolo Ardoino reaffirmed his company’s continued investment in Bitcoin and gold, stating that both assets represent enduring value. This stance strengthens confidence across the digital asset market, highlighting institutional interest even in bearish conditions.

Strategy Stock Sees Short-Term VolatilitySource: Google Finance

Following the announcement, Strategy Inc.’s Class A shares dropped by 4.84%, closing at $304.79. The stock had fallen from a previous close of $320.29, testing intraday support near $285 before rebounding modestly. However, pre-market trading showed a slight recovery of 1.15% to $308.30, indicating early signs of stabilization.

Earnings Playbook for the Week Ahead Retail investors are preparing for the kick-off of the third-quarter earnings season, with big banks and other top stocks reporting this week.

Here’s a look at some retail favorites that individual investors will be watching.

FAST stock is moving. See the real-time price action here.
Monday, Oct. 13Before Market Open Fastenal Company (NASDAQ:FAST) kicks off the week with its third-quarter earnings report ahead of Monday’s opening bell. Analysts expect the company to report earnings of 30 cents per share on revenue of $2.13 billion, according to estimates from Benzinga Pro.

Read Next: IREN Stock’s 50% Spike Powered By Nvidia GPUs

Investors will be watching for a bump in sales from Fastenal’s digital initiatives and expanded customer contracts, with improved margins enabled by cost controls.

Tuesday, Oct. 14Before Market OpenSeveral big banks including JPMorgan Chase & Co. (NYSE:JPM), Wells Fargo & Company (NYSE:WFC), Citigroup Inc. (NYSE:C) and The Goldman Sachs Group, Inc. (NYSE:GS) report before Tuesday’s opening bell.

Johnson & Johnson (NYSE:JNJ), Domino’s Pizza, Inc. (NYSE:DPZ), Ericsson (NASDAQ:ERIC) and Albertsons Companies, Inc. (NYSE:ACI), Albertsons Companies, Inc. (NYSE:ACI) and the largest asset manager in the world, BlackRock, Inc. (NYSE:BLK), will also report before the market opens.

Wednesday, Oct. 15Before Market OpenSemiconductor machinery provider ASML Holding N.V. (NASDAQ:ASML) will release its Q3 earnings report ahead of Wednesday’s opening bell.

Analysts forecast earnings per share of $6.36 and revenue of $8.81 billion, showing year-over-year growth and strength in demand.

Read Next: Datavault AI Stock’s Face-Melting 720% Rally—What To Know

Wednesday’s batch of bank earnings includes Morgan Stanley (NYSE:MS), Bank of America Corp (NYSE:BAC), Synchrony Financial (NYSE:SYF) and The PNC Financial Services Group, Inc. (NYSE:PNC) all reporting before the bell.

Abbott Laboratories (NYSE:ABT) and Prologis, Inc. (NYSE:PLD) are also set to report on Wednesday morning.

After Market CloseUnited Airlines Holdings, Inc. (NASDAQ:UAL) is set to release its Q3 financial results after Wednesday’s closing bell. The Street is looking for EPS of $2.62 on revenue of $15.32 billion for the quarter.

Thursday, Oct. 16, 2025Before Market OpenTaiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) will release its Q3 earnings report before the market opens on Thursday.

Analysts estimate earnings per share of $2.59 and quarterly revenue of $31.5 billion, propelled by advanced chip demand for AI applications.

​Last Friday, Susquehanna analysts maintained a Positive rating on TSMC and raised the price target from $300 to $400.

TSMC continues to outperform, with its leadership in cutting-edge chip fabrication and strong year-to-date stock performance

Read Next— Space Stock Tracker: RocketLab Hits New Highs, AST Partners With Verizon

The banks are back on Thursday with The Charles Schwab Corporation (NYSE:SCHW), KeyCorp (NYSE:KEY), The Bank of New York Mellon Corp. (NYSE:BK) and U.S. Bancorp (NYSE:USB) set to report before the opening bell.

Infosys Limited (NYSE:INFY) and The Travelers Companies, Inc. (NYSE:TRV) will also report on Thursday morning.

After Market CloseRailroad operator CSX Corporation (NASDAQ:CSX) and brokerage firm Interactive Brokers Group, Inc. (NASDAQ:IBKR) will report after Thursday’s closing bell.

Friday, October 17, 2025Before Market Open

Another slew of banks like American Express Company (NYSE:AXP), Ally Financial Inc. (NYSE:ALLY), Regions Financial Corp. (NYSE:RF), Huntington Bancshares Inc. (NASDAQ:HBAN) and Truist Financial Corp. (NYSE:TFC) will report earnings on Friday morning.

Oilfield-services company SLB Ltd. (NYSE:SLB) closes out the week with its third-quarter report.

Read Next: 

Rigetti Vs. Infleqtion: Citron Weighs In On Quantum ‘Raging Bulls’
Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

FERRARI N.V.: PERIODIC REPORT ON THE BUYBACK PROGRAM

Maranello (Italy), October 13, 2025 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 360 million share buyback program announced on July 31, 2025, as the eighth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the “Eighth Tranche”), the additional common shares - reported in aggregate form, on a daily basis - on the Euronext Milan (EXM) as follows:

 Trading
Date
(dd/mm/yyyy)

 Stock Exchange

 Number of common shares purchased

 Average price per share
excluding fees
(€)

 Consideration excluding fees

(€)

06/10/2025EXM11,600424.64314,925,859.9607/10/2025EXM7,700423.50913,261,020.0708/10/2025EXM11,500420.79634,839,157.4509/10/2025EXM59,500366.741021,821,089.5010/10/2025EXM11,200354.49753,970,372.00Total-101,500382.438438,817,498.98 (*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchase

            Since the announcement of such Eighth Tranche till October 10, 2025, the total invested consideration has been:

Euro 149,602,206.82 for No. 371,924 common shares purchased on the EXM USD 33,447,541.72 (Euro 28,547,995.07*) for No. 69,609 common shares purchased on the NYSE. As of October 10, 2025, the Company held in treasury No. 16,115,828 common shares, net of shares assigned under the Company’s equity incentive plan, corresponding to 8.31% of the total issued common shares. Including the special voting shares, the Company held in treasury 8.86% of the total issued share capital.
Since the start of the multi-year share buyback program of approximately Euro 2 billion announced during the 2022 Capital Markets Day, on July 1, 2022, until October 10, 2025, the Company has purchased a total of 5,452,553 own common shares on EXM and NYSE, including transactions for Sell to Cover, for a total consideration of Euro 1,820,719,899.24.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Ferrari’s corporate website under the Buyback Programs section (https://www.ferrari.com/en-EN/corporate/buyback-programs).

FNV BB PR 13 October 2025 ENG

A view shows the logo of the Organization of the Petroleum Exporting Countries (OPEC) outside its headquarters in Vienna, Austria, May 28 , 2024. REUTERS/Leonhard Foeger Purchase Licensing Rights, opens new tab

LONDON, Oct 13 (Reuters) - OPEC made no changes on Monday to its relatively high global oil demand growth forecasts for this year and next, and implied the oil market will see a much smaller supply deficit in 2026 as the wider OPEC+ group pushes ahead with output increases.

OPEC+ is adding more crude to the market after the Organization of the Petroleum Exporting Countries, Russia and other allies decided to unwind some output cuts more rapidly than earlier scheduled. The extra supply has raised concern of a surplus and weighed on oil prices this year.

Sign up here.

In a monthly report on Monday, OPEC said the world economy was maintaining a solid growth trend.

While demand is seen as steady, OPEC said that OPEC+ in September raised crude output by 630,000 barrels per day to 43.05 million bpd, reflecting its earlier decisions to increase output quotas.

Expected demand for OPEC+ crude at an average 43.1 million bpd implies that the world market will see a deficit of 50,000 bpd if the wider group keeps pumping at September's rate, according to a Reuters calculation based on the report.

Last month's report implied a deficit of 700,000 bpd in 2026 if OPEC+ kept pumping at August's rate.

Editing by Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Highlights

Impurity Removal Metallurgical Tests Yield Allanite Rare Earths Processing Breakthrough: Impurity removal is one of the last steps in the hydrometallurgical processing of rare earths elements (“REE”) and is performed to remove non-REE minerals from the leach liquor prior to solvent extraction and separation (i.e. the final steps before producing rare earths oxide). Historically, this has been a challenging step for processing allanite-based REEs, like Halleck Creek’s ore, as the mineral typically produces unwanted byproducts such as gypsum and silica gel, resulting in additional and difficult processing steps to remove them.In a recent and extensive impurity removal test program on Halleck Creek ore minimal gypsum and silica gel were formed during the process, which points to immense operating benefits, including but not limited to the reduction of rare earths yield loss and fewer processing steps resulting in potentially lower capital and operating expenses.These results de-risk what has historically been a material technical and economic hurdle in the processing of allanite-based rare earths elements (i.e. Halleck Creek’s ore) and represent a major milestone in unlocking Halleck Creek’s vast REE supply potential.     Adverse Elements removed from Leachate Solutions Effectively 100% of iron, titanium and other deleterious elements precipitated from Leachate SolutionsOver 99% of silica and aluminum precipitated from Leachate Solutions Magnesium Oxide (MgO) chosen as the optimal neutralizing reagent DENVER, Oct. 13, 2025 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) (“ARR” or the “Company”) has successfully completed a critical stage in its mineral processing program, the first phase of impurity removal testing, with highly encouraging results. This milestone confirms that key contaminants like iron, aluminum, silica and others can be effectively removed from Halleck Creek ore, paving the way for efficient rare earths extraction. Importantly, the tests showed minimal formation of problematic by-products like gypsum and silica gel, a common challenge in processing allanite-based rare earths elements.

SGS completed the neutralization testing at their laboratory in Lakefield, Ontario, Canada. The results will be a key input in the hydrometallurgical processing portion of the Pre-Feasibility Study flowsheet. The objective of impurity removal is to remove deleterious elements (such as iron, aluminum, silica and others) from the rare earth elements (“REE”) in leachate solutions. Impurity removal is the next processing step after leaching1 and is accomplished by adding reagents to neutralize the leach liquor at specific pH ranges. At different pH levels, the various deleterious elements precipitate out and are removed from the leach solution by filtration. Throughout this robust testing program, ARR’s third-party lab, SGS tested various reagents over various pH ranges to determine the optimal conditions for Halleck Creek. The next step of hydrometallurgical testing will be to create a mixed rare earth oxide, which is a precursor to solvent extraction and creating individual, separated oxides used in permanent magnets.

Six potential neutralizing agents were tested on REE enriched leach solutions. Magnesium oxide (MgO) and magnesium carbonate (MgCO3) yielded the best results. Looking forward, magnesium oxide is a more cost-effective reagent than magnesium carbonate and was selected as the optimal neutralizing reagent for the mineral processing flow-sheet.

Given allanite (i.e. REE host mineral) is rich in calcium and silica, it was anticipated that gypsum (i.e. calcium sulfate) and/or silica gel might form during the impurity removal test program. The solutions neutralized with MgO formed few of these unwanted products, which will likely yield significant operational benefits, including but not limited to reduction of REE yield loss, fewer additional processing steps and lower capital and operating expenses. Historically, the formation of these products has proven to be a material technical and economic hurdle to overcome in the processing of allanite-based rare earths.

The primary neutralization using 15% MgO for 2 hours at 75oC and pH 3.15 (i.e. test PN12) removed 99.8% iron, 89.0% silica, 92.9% thorium, and 99.4% titanium with an average REE loss for light (“LREE”) and heavy rare earths (“HREE”)2 of 0.6% and 0.8%, respectively. Furthermore, 40.5% aluminum was removed during primary neutralization, which is greater than anticipated. The secondary neutralization (i.e. test SN2) using between 5% and 10% MgO for 2 hours at 75oC and pH of 5.0 removed 99.4% Iron, 96.3% aluminum, 71.0% silica, 98.9% Thorium, and 95.6% Titanium from what was left in the solution after the primary neutralization. An average of 7.6% of LREE and 16.7% of the HREE were precipitated during secondary neutralization. Our technical consultants recommend recycling the solids from secondary neutralization back to leaching to capture the REE for reprocessing.

Why it matters?

Impurity removal testing was performed on leachate solutions prepared from mineral concentrate material collected from four core holes at Halleck Creek as previously released3. The main goal of the neutralization tests is to remove impurities (i.e. non-rare earth elements) from the leach liquor containing the dissolved REEs through precipitation, while minimizing the loss of REEs through co-precipitating alongside the impurities.

Impurity removal is a key step in producing rare earth products from Halleck Creek ore. The tests were completed ahead of schedule and the data received will be used in the mineral processing flow-sheet design for the upcoming Pre-Feasibility Study (“PFS”). Removing non-REE elements from leachate solutions enables the REE to be extracted from solution via solvent extraction and ultimately produce separated rare earth oxides (precursors for rare earths permanent magnets). Iron, silica, aluminum and other deleterious elements can contaminate the solvent extraction process and must be removed from the leachate beforehand. The impurity removal testing demonstrated that these elements can removed from leachate solutions thus providing a highly enriched and clean solution for rare earth product refining. The successful completion of these tests is a major metallurgical processing milestone for Halleck Creek’s allanite based rare earths.

Metallurgical Testing Next Steps

Hydrometallurgical testing is nearing completion.SGS will then create a mixed rare earth oxalate by precipitating the REE with oxalic acid.The mixed rare earth oxalate will be calcined to create a mixed rare earth oxide (i.e. the precursor to separated rare earth oxides).The mixed rare earth oxide will be re-leached. Cerium oxide is insoluble in the leach reagent and will be filtered out of the new leachate solution. The final leachate solution is then ready for future solvent extraction testing. ARR expects these final tests to be completed before the end of the year. In parallel, bulk samples from the CSM test pit have been delivered to Fl Smidth, Loesche and Weir (Corem) for comminution optimisation testing which is currently in progress. These results will be reported to the market as soon as they are complete.

Additional Technical Details

Impurity removal testing was performed on leachate solutions prepared from mineral concentrate material collected from four core holes at Halleck Creek as previously released4.

In general, iron, silica, and thorium become insoluble in solutions with pH values between 2.75 and 3.25 and precipitated out. REEs generally remain in solution at these same pH ranges. Therefore, by raising the pH of the leachate solution, iron, silica and thorium can be precipitated and removed via filtration while REE stays in solution. This is called primary neutralization.

Aluminum and uranium generally become insoluble in solutions with pH values between 4.5 and 6.0. REE generally remain in solution at these same pH ranges. Increasing pH of the solution in secondary neutralization, iron, thorium, aluminum, and uranium can be precipitated and removed via filtration from solution.

By performing impurity removal in two neutralization steps, fewer REE are precipitated because the chemical reactions are more controlled. If the pH of the leachate solution was suddenly increased to above 3.5, losses of REE through co-precipitation would occur as a result.

Different reagents react differently with chemical elements in various leachate solutions. SGS performed a comprehensive series of tests to determine which chemical reagents and pH values are most effective on Halleck Creek leachate solutions.

Reagent Selection

SGS, in Lakefield Ontario, tested six leach liquor neutralization reagents for impurity removal from leach solutions including:

Magnesium oxide (MgO)Magnesium carbonate (MgCO3)Sodium hydroxide (NaOH)Sodium carbonate (soda ash)Limestone (calcium carbonate)Lime (CaO) SGS performed pH profile testing over a range of pH values from 2.5, 3.0, 3.5, 4.0, and 4.5 for each reagent, PN1 through PN 6. Table 1 and Figure 1, and Figure 2 summarize the results of the tests. The tests were all performed at 75oC and the reagent strengths varied between reagent types.

Magnesium oxide and magnesium carbonate performed well in testing. Iron (Fe) and thorium (Th) were precipitated at high levels, while REE precipitation was low across the pH ranges tested. Figure 1 below shows that at pH less than 3.5, Nd and Dy have minimal precipitation. Conversely, Figure 2 shows that Fe and Th have over 80% precipitation when pH is less than 3.5.

The limestone and lime performed poorly because they precipitated gypsum and co-precipitated rare earth elements from the leach solution.

The sodium hydroxide and soda ash also performed poorly because they formed sodium/rare earth double salts and precipitated rare earth elements from the leach solution.

Conversely, to the calcium- and sodium-based reagents, solutions neutralized by MgO did not exhibit formation of gypsum or silica gel during the course of testing. SGS and Tetra tech attribute this to the reagent type, dilution, the temperature of the solutions, and the short residence times of testing.

Table 1 – pH Profile Testing Results for Primary Neutralization by Reagent Type and pH Range

Figure 1 – pH Profiling Charts for Nd and Dy

Figure 2 - pH Profile Charts for Fe and Th

Primary Neutralization (“PN”)

The pH profile tests clearly showed that MgO and MgCO3 were superior to the other reagents for impurity removal and rare earth recovery. SGS compared MgO and MgCO3 for primary neutralization at a static pH of 3.25. The tests results were very similar. Tetra Tech engineers determined that MgO is a more cost-effective reagent than MgCO3 when considering dosage rates and the cost of the reagents. Therefore, MgO was selected as the reagent for primary neutralization. It is important to note that both MgO and MgCO3 did not form gypsum or silica gel in the neutralization process. Historically, the formation of these products has proven to be a material technical and economic hurdle to overcome in the processing of allanite-based rare earths.

With the selection of MgO as the neutralization reagent, SGS performed detailed pH endpoint tests for pH ranges from 2.75, 3.0, and 3.25, tests PN7, PN9, and PN10, respectively, see Table 3 and Figure 3. These tests indicate that a target pH of 3.15 is the optimal pH for primary neutralization. Test PN13 was then performed using a pH of 3.15, confirming this value.

Table 3 – Endpoint pH Comparison of Primary Neutralization for MgO

Figure 3 - pH Profile Charts for MgO

SGS performed two additional tests, PN12 and PN14. Tests PN12 and PN14 were conducted using commercially available MgO products near Halleck Creek as a comparison to the locally available MgO used in the other tests.

Test PN13 reduced the residence time of primary neutralization from 2 hours to 1 hour. Reducing the residence time to one hour reduces equipment size and reduces REE losses to precipitation, which ultimately will increase overall rare earth oxide recoveries.

Table 3 – Comparison of Residence Time in Primary Neutralization

Secondary Neutralization (“SN”)

To remove the remaining iron, silica, aluminum, uranium and thorium from solution, SGS performed a pH profile test, SN1, for nominal pH ranges from 4.0, 4.5, 5.0, 5.5 and 6.0, see Table 5. Figure 4 below shows that nearly all the remaining iron, aluminum and thorium are precipitated at a pH near 5.0. Figure 4 also shows that Dy is starting to precipitate at pH 5.0.

Endpoint pH tests were conducted using pH values of 5.0 and 5.25, tests SN2 and SN3, respectively, see Table 5. Based on these two observations, SGS and the ARR team determined that secondary neutralization is best achieved at a target pH of 5.0.

A final leachate solution was prepared by using leachate from test PN11 using the parameters in test SN2. The resulting leach solution will be used for bench scale ion exchange removal of residual uranium and to feed into oxalic acid precipitation to produce a mixed rare earth oxalate. These tests will be completed prior to the end of the year.

Table 5 – Secondary Neutralization Tests

Figure 4 - pH Profile Charts for Secondary Neutralization

It should be noted, to prevent REE losses in the system, SGS and Tetra Tech recommend that the precipitated solids generated during secondary neutralization be recycled to the leach circuit andre-dissolved. While this increases the total volume of material being leached by about 1% or 2%, capturing the REE in this material is most beneficial for the project.

This release was authorized by the board of American Rare Earths.

Investors can follow the Company’s progress at www.americanree.com

The complete JORC Report can be found here:

About American Rare Earths Limited:

American Rare Earths (ASX: ARR | OTCQX: ARRNF | ADR: AMRRY) is a critical minerals company at the forefront of reshaping the U.S. rare earths industry. Through its wholly owned subsidiary, Wyoming Rare (USA) Inc. (“WRI”), the company is advancing the Halleck Creek Project in Wyoming—a world-class rare earth deposit with the potential to secure America’s critical mineral independence for generations. Located on Wyoming State land, the Cowboy State Mine within Halleck Creek offers cost-efficient open-pit mining methods and benefits from streamlined permitting processes in this mining-friendly state.

With plans for onsite mineral processing and separation facilities, Halleck Creek is strategically positioned to reduce U.S. reliance on imports—predominantly from China—while meeting the growing demand for rare earth elements essential to defense, advanced technologies, and economic security. As exploration progresses, the project’s untapped potential on both State and Federal lands further reinforces its significance as a cornerstone of U.S. supply chain security. In addition to its resource potential, American Rare Earths is committed to environmentally responsible mining practices and continues to collaborate with U.S. Government-supported R&D programs to develop innovative extraction and processing technologies for rare earth elements.

For further information contact:

1 See ASX Release dated July 16, 2025
2 Light Rare Earths include La, Ce, Pr and Nd. Heavy rare earths include Sm, Eu, Gd, Tb and Dy.
3 ASX Release 16 July, 2025
4 ASX Release 16 July, 2025

Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08e80a81-df57-4dbc-80d7-e5faa9e7dfd7

https://www.globenewswire.com/NewsRoom/AttachmentNg/4e2d9026-77cc-46e3-a73d-849a948169fc

https://www.globenewswire.com/NewsRoom/AttachmentNg/aac0fe38-559c-4289-b07f-9320cbf3ee41

https://www.globenewswire.com/NewsRoom/AttachmentNg/f21c5df0-9aaa-4bef-ad0a-5712a6c53093

https://www.globenewswire.com/NewsRoom/AttachmentNg/49760699-2f78-4d74-9e36-c720cde48044

https://www.globenewswire.com/NewsRoom/AttachmentNg/22f8f86f-5a23-4a01-bf77-d73d03ef9a35

https://www.globenewswire.com/NewsRoom/AttachmentNg/f72cacbd-11f0-4e72-bc14-92ce461208d6

https://www.globenewswire.com/NewsRoom/AttachmentNg/c5ac1beb-a7c9-44a2-9bf1-24e8dc4cee22

https://www.globenewswire.com/NewsRoom/AttachmentNg/db29e893-c733-4901-a36a-165092b6da67

https://www.globenewswire.com/NewsRoom/AttachmentNg/b1370211-20a0-47d8-b738-33342f963ee9

-

CAMAS, Wash.--(BUSINESS WIRE)--nLIGHT, Inc. (Nasdaq: LASR), a leading provider of high-power lasers for mission critical directed energy, optical sensing, and advanced manufacturing applications, announced that it will release its financial results for the third quarter of 2025 after the financial markets close on Thursday, November 6, 2025.

A webcast to discuss the third quarter results will be held on Thursday, November 6, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The audio webcast will be available on the investor relations section of the company's web site at http://investors.nlight.net. A replay of the webcast will be available shortly after the conclusion of the call.

The webcast can also be accessed directly at https://events.q4inc.com/attendee/876155821.

About nLIGHT

nLIGHT, Inc. is a leading provider of high-power lasers for mission critical directed energy, optical sensing, and advanced manufacturing applications. Headquartered in Camas, Washington, nLIGHT employs approximately 800 people with operations in the United States, Europe and Asia. For more information, please visit www.nlight.net.

More News From nLIGHT, Inc.

Back to Newsroom

Headlines:

Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1
Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2
Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic acids.3
, /PRNewswire/ -- Waters Corporation (NYSE: WAT) today unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterization for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology. With the rapid growth of cell and gene therapies, mRNA, and complex protein therapeutics, scientists face significant challenges in analyzing increasingly large and heterogeneous drug modalities – yet existing tools are limited in resolution, sensitivity, and compliance-readiness. The Xevo CDMS System addresses these gaps with direct, individual-particle mass measurement for molecules up to 150+ MDa, enabling previously unattainable analysis of protein complexes, nucleic acids, lipid nanoparticles, viral vectors, and more.

The Waters Xevo CDMS provides confident analysis of new modalities, like empty, partial, and full viral vector capsids, using up to 100-fold less sample volume than that required by current techniques, and delivering results in less than ten minutes.

"Waters continues to make strategic investments in large molecules, recognizing that advanced tools for bioanalytical characterization play a critical role in driving therapeutic breakthroughs. Today, we are proud to introduce the first-of-its-kind Xevo Charge Detection Mass Spectrometer, enabling the precise analysis of previously unmeasurable molecules," said Udit Batra, Ph.D., President and Chief Executive Officer, Waters Corporation. "We believe the Xevo CDMS will accelerate the global development of genetic medicines and other advanced modalities by providing a greater understanding of the characteristics of large molecules earlier in development, which is crucial for making life-changing therapies more accessible to patients."

The Waters Xevo CDMS provides confident analysis of new modalities, like empty, partial, and full viral vector capsids, using up to 100-fold less sample volume than that required by current techniques, and delivering results in less than ten minutes, even at concentrations as low as 1010 vp/mL. This new capability paves the way for real-time characterization of gene therapies during process development – ultimately improving the safety and efficacy of advanced therapies. Additionally, CDMS absolves the need for deconvolution or digestion approaches to achieve simple and accurate analysis of complex molecules. This transformational mass spectrometry advancement supports a wide range of applications – from discovery and research, through process development, to regulatory approval and manufacturing.

"Our mission is to accelerate the development of gene therapies for genetically mediated cardiovascular diseases and Alzheimer's, where there is a significant unmet need in treatment options," said Timothy Fenn, Ph.D., Vice President, Analytical Development and Quality Control, Lexeo Therapeutics. "With CDMS, we're asking questions we didn't know we could ask. It's a game-changer for our analytical workflows, enabling us to generate accurate, reproducible results in minutes."

At the heart of the Xevo CDMS is the Electrostatic Linear Ion Trap (ELIT), which provides direct measurement of individual ions through simultaneous measurement of their mass-to-charge ratio and mass. The novel technology was developed by Indiana University and Megadalton Solutions, founded by Distinguished Professors Martin Jarrold and David Clemmer at Indiana University. Waters acquired the technology assets and intellectual property rights of Indiana University in 2022 to accelerate its path to commercialization.

The Waters Xevo CDMS System is powered by the GxP-ready waters_connect™ Software and is available to order now.

ABOUT:  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food and the purity of water, and the quality and sustainability of products used every day. In over 100 countries, our 7,600+ passionate employees collaborate with customers in laboratories, manufacturing sites, and hospitals to accelerate the benefits of pioneering science.

Waters, Xevo, and waters_connect are trademarks of Waters Technologies Corporation.

Additional Resources:

Product Page 
Contact:

Molly Gluck
Head of External Communications
Waters Corporation
[email protected]
Mobile: +1.617.833.8166

References:

1 Demonstrated mass analysis on-instrument of various molecular species from <100 kDa to Chikungunya Virus complexes of >150 MDa. 

2 Time taken to acquire a statistically representative number of ions to enable characterization of AAV features.

3 Indicative of amount of sample required for sample preparation. Actual sample consumed during analysis is <5 µL. 

SOURCE Waters Corporation

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Photo illustration by Cheng Xin/Getty Images

Getty Images

AST SpaceMobile stock (NASDAQ:ASTS) soared nearly 32% last week and has risen almost 4x year-to-date. The company is constructing a space-based cellular broadband network that connects directly to standard smartphones without requiring additional hardware for commercial and governmental utilization. The recent increase followed the announcement of a significant commercial partnership with Verizon to offer space-based cellular coverage throughout the continental U.S. beginning in 2026. This agreement enhances an initial strategic partnership from last year by formalizing the commercial rollout, integrating AST’s satellite network with Verizon's terrestrial infrastructure, and expanding Verizon’s 850 MHz spectrum coverage into remote regions. The agreement fortifies AST’s position against rivals such as SpaceX's Starlink and assists in strengthening its relationships with leading U.S. telecom providers.

ASTS stock has experienced a substantial rise recently, yet there is considerable risk in depending on a single stock. Conversely, there is great value in a broader diversified strategy we adopt with the Trefis High Quality Portfolio. Additionally, ponder what the long-term performance of your portfolio could look like if you combined 10% commodities, 10% gold, and 2% crypto with equities.

What Does AST Do?There is a continuous competition to establish broadband services via satellites, with Elon Musk’s SpaceX currently leading with over 8,000 Starlink satellites already in orbit. However, AST SpaceMobile’s approach diverges in crucial ways. While Starlink focuses on consumers directly by offering hardware and internet subscriptions, AST’s satellites are engineered to operate like space-based cell towers, integrating directly into the networks of existing mobile operators such as AT&T, Vodafone, Rakuten, and Verizon.

This strategy allows users to access connectivity through these satellites using their regular smartphones and current SIM cards, helping to remove coverage dead zones. During its Q2 2025 earnings report, the company stated that it had verified a plan to launch 45 to 60 satellites into orbit by 2026 to energize cellular-based broadband networks. The firm aims to conduct orbital launches every one to two months on average throughout 2025 and 2026 and mentioned that the satellites are fully funded.

A Good Proposition For Wireless Carriers?For telecom providers, the value proposition is considerable. Collaborating with AST enables them to extend 4G and 5G coverage into deserts, oceans, mountainous regions, and other underserved locales where conventional towers are not financially viable. This allows them to offer truly nationwide or even global coverage to clients. These advantages can enhance customer satisfaction and open new revenue opportunities without telecom providers needing to incur the substantial costs associated with rural infrastructure.

Instead of advertising directly to consumers, AST generates revenue by charging telecom providers for access to its satellite capacity, with pricing determined by usage or through long-term contracts. This model could afford AST a recurring, high-margin revenue stream while solidifying deep partnerships across the international telecom sector. AST has reportedly engaged with over 50 mobile network operators globally, enabling them to serve nearly 3 billion subscribers.

Valuation Is All About The FutureWith a market capitalization of approximately $31 billion, ASTS is trading at over 500x the consensus revenue projection for 2025 of $60 million and 120x the estimated revenue for 2026. This represents a steep valuation considering that the company is still in the nascent stages of its operations. Nonetheless, growth has been rapid, although on a small base, with revenues increasing 249% over the previous year to $4.9 million. See ASTS Revenue Comparison. Losses remain substantial, with operating losses amounting to $260 million over the last 12 months. ASTS has performed significantly worse than the S&P 500 index during various economic downturns.

During the 2022 inflation shock market crash, ASTS stock plummeted 68.5% from a peak of $22.50 on February 9, 2021, to $7.08 on June 1, 2021, compared to a peak-to-trough decline of 25.4% for the S&P 500. Read ASTS Dip Buyer Analyses to learn how the stock has bounced back from sharp declines in the past. Nonetheless, the company continues to possess a robust balance sheet, with $924 million in cash and cash equivalents, a debt-to-equity ratio of merely 4.3%, and cash accounting for nearly half of its total assets. This financial flexibility ought to provide AST the necessary runway to implement its satellite deployment strategy, although investors will need to exercise patience as the company transitions from technology deployment to commercial-scale revenue generation.

Robust demand is one of the factors we consider in our High-Quality portfolio, which has surpassed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 105% since its inception. What accounts for this? As a collective group, HQ Portfolio stocks have provided better returns with lower risk compared to the benchmark index; experiencing less volatility, as illustrated in HQ Portfolio performance metrics.

, /PRNewswire/ -- abrdn Global Infrastructure Income Fund (NYSE: ASGI) ("ASGI" or the "Acquiring Fund) and abrdn Japan Equity Fund, Inc. (NYSE: JEQ) ("JEQ" or the "Acquired Fund"), announce today the completed reorganization of the Acquired Fund with the Acquiring Fund after close of business on October 10, 2025.

In the reorganization, common shareholders of JEQ received an amount of ASGI common shares with a net asset value equal to the aggregate net asset value of their holdings of JEQ common shares, as determined at the close of regular business on October 10, 2025.

Relevant details pertaining to the reorganization are as follows:

Acquiring Fund

Acquired Fund

Acquiring Fund
NAV per Share ($)
10/10/25

Conversion Ratio

ASGI

JEQ

$20.9590

0.378399

There are no proposed changes to the current investment objective, strategies, structure, or policies of the Acquiring Fund as a result of the reorganization.

Important Information

In the United States, Aberdeen Investments refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.

The information in this press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities or the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.

Closed end funds | Aberdeen

SOURCE Aberdeen Investments U.S. Closed End Funds

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Photo illustration by Cheng Xin/Getty Images

Getty Images

American Express (NYSE:AXP) is scheduled to announce its earnings on Friday, October 17, 2025. Revenues are expected to reach $18 billion, reflecting an 8.5% increase year-over-year according to consensus estimates, while earnings are anticipated to be approximately $3.28 per share, which is a 6.5% rise compared to the previous year. This growth is likely to be fueled by increased spending by cardholders and a rise in net card fees, primarily driven by greater penetration of premium products and robust retention rates. The international segment may also perform well, bolstered by higher merchant acceptance.

The company’s current market capitalization stands at $229 billion. Over the past twelve months, revenue was $69 billion, and net income was approximately $10 billion. While many factors will determine how the results compare to consensus and expectations, grasping historical patterns could improve the odds in your favor if you are an event-driven trader.

There are two approaches to achieving this: comprehend the historical odds and position yourself ahead of the earnings announcement, or analyze the relationship between immediate and medium-term returns following earnings, and position yourself appropriately once the earnings are disclosed. That being said, if you are looking for upside with lower volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – it has outperformed the S&P 500 and achieved returns exceeding 105% since its inception.

See earnings reaction history of all stocks

American Express’s Historical Odds Of Positive Post-Earnings Return

Here are some insights regarding one-day (1D) post-earnings returns:

There have been 20 earnings data points recorded over the past five years, with 7 positive and 13 negative one-day (1D) returns observed. In total, positive 1D returns occurred about 35% of the time.However, this percentage drops to 25% if we examine data from the last 3 years instead of 5.The median of the 7 positive returns is 6.2%, while the median of the 13 negative returns is -2.7%.Additional data for observed 5-Day (5D) and 21-Day (21D) returns after earnings are summarized along with the statistics in the table below.

1D, 5D, and 21D Post Earnings Return

Trefis

Correlation Between 1D, 5D, and 21D Historical ReturnsA relatively less risky approach (although ineffective if the correlation is low) is to analyze the correlation between short-term and medium-term returns following earnings, identify a pair that demonstrates the highest correlation, and make the appropriate trade. For instance, if 1D and 5D exhibit the strongest correlation, a trader might consider positioning themselves “long” for the next 5 days if the 1D post-earnings return is positive. Below is some correlation data based on both a 5-year and a more recent 3-year history. Note that the correlation 1D_5D refers to the relationship between 1D post-earnings returns and subsequent 5D returns.

Correlation Between 1D, 5D, and 21D Historical Returns

Trefis

Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (comprising the S&P 500, S&P mid-cap, and Russell 2000), delivering strong returns for investors. Additionally, if you desire upside with a smoother experience than an individual stock like American Express, explore the High Quality portfolio, which has surpassed the S&P and achieved 105% returns since its inception.

Bloom Energy stock jumped after agreeing to a partnership with Brookfield Asset Management.

WASHINGTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a business development update, including a supply agreement for the largest quantity of enriched silicon-28 received by the Company to date and a strategic acquisition of a radiopharmacy in the United States to complement and expand the operations of PET Labs Pharmaceuticals (Pty) Ltd (“PET Labs”), the Company's South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.

The Organization of the Petroleum Exporting Countries pointed to high debt levels in key economies and tariff uncertainty as areas of concern.

If the run-up to Rachel Reeves' Budget next month has left investors wary of British banks, UBS is not joining the caution.

Its analysts have kept their “overweight” stance on the sector, arguing that cheap valuations and strong earnings momentum make the risk worth taking.

They say most traditional long-only investors are sitting tight until after the 26 November budget, unsure how the Treasury plans to plug what it calls a fiscal gap of £10–$30 billion.

Hedge funds, though, are reportedly more upbeat, spotting value in the sector’s solid returns on tangible equity, faster loan growth and improving deposit mix.

UBS thinks these trends will translate into the strongest revenue growth of any European banking market over the next couple of years.

Its top picks are the domestically focused names (Barclays PLC (LSE:BARC), NatWest Group PLC (LSE:NWG) and Paragon Banking Group PLC (LSE:PAG))alongside Standard Chartered among the internationals.

HSBC, by contrast, is rated neutral. UBS expects the coming third-quarter results season to extend the healthy momentum seen in the spring.

The key political question is whether the budget brings another tweak to the bank surcharge, which currently sits at 3%. UBS thinks a rise to around 5% is plausible, but expects any impact to be passed on to customers rather than eating into profits.

The bank doubts the government will pursue wider changes, arguing ministers still see a strong financial services sector as central to economic growth and investment.

Mortgage lending could slow into the autumn as landlords and buyers wait to see whether stamp duty or buy-to-let tax changes are in store. UBS is sceptical that higher landlord taxes would do anything to ease Britain’s housing shortage.

Earnings forecasts remain robust. The bank expects the UK lenders to grow earnings per share by between 4% and 19% in 2025, by 27% in 2026, and by 6% to 17% in 2027.

Returns on tangible equity are expected to hold at around 14.7% to 15% over the period, supporting dividend yields of roughly 8.5% to 9.2%.

On valuation, UBS notes the domestics trade at just 7.9 and 7.1 times forecast 2026 and 2027 earnings, cheaper than their continental peers.

Even the international names, at around nine times, still look good value. Policy risk may be keeping sentiment gloomy, but on these numbers the City’s big banks could yet turn out to be the contrarian’s friend.

15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months
Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed in 86% of patients in Year 1, 91% in Year 2, and 95% in Year 3
No new safety events observed during long-term follow-up

, /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term follow-up data demonstrating durable responses to PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). These data were presented at the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting. PAPZIMEOS was granted full approval by the United States Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP.

PAPZIMEOS approval was supported by results from the pivotal study, which successfully met its primary safety and pre-specified primary efficacy endpoints. PAPZIMEOS was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. 51% (18 out of 35) of study patients achieved complete response (95% CI: 34-69%), requiring no surgeries in the 12-month period after treatment with PAPZIMEOS. Results from the pivotal clinical study of PAPZIMEOS were published in The Lancet Respiratory Medicine.

Key data highlights from the AAO-HNSF presentation:

15 out of the 18 complete responders (83%) in the pivotal study demonstrated ongoing complete responses as of the September 19, 2025 data cutoff, with:

Median duration of follow-up of 36 months (range: 27-37 months);
Median duration of complete response yet to be reached; and
No new safety events observed during long-term follow-up.

Prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. The percent of patients with a decrease in the number of surgeries, compared to pre-treatment was:

86% in Year 1;
91% in Year 2; and
95% in Year 3.

"The updated durability data reinforce that PAPZIMEOS is not only a medical breakthrough but a transformative therapy for the RRP community," said Helen Sabzevari, PhD, President and CEO of Precigen. "For patients and their families, sustained responses mean freedom from the relentless cycle of repeat surgeries, reduction in the risk of surgical damage, and the possibility to improve quality of life. For physicians, it provides confidence in a safe and effective therapy that addresses the root cause of disease. And for the healthcare system, durable responses translate into fewer procedures, reduced complications, and lower long-term burden of care. This is precisely the type of impact we envisioned when we set out to develop what would become the first FDA-approved therapy for adults with RRP."

About RRP
RRP is a rare, debilitating, and potentially life-threatening disease of the upper and lower respiratory tract caused by chronic HPV 6 or HPV 11 infection. RRP can lead to severe voice disturbance, compromised airways, and recurrent post-obstructive pneumonia. Although rare, RRP has the potential for transformation to malignant cancer and can be fatal. Management of RRP has primarily consisted of repeated surgeries, which do not address the underlying cause of the disease and can be associated with significant morbidity as well as significant patient and health system burden. As the number of lifetime surgeries increases, the risk for irreversible iatrogenic laryngeal injury increases with each surgery, and patients may undergo hundreds of these surgeries over their lifetimes. RRP can impact patients' work and social lives, financial stability, and mental health. Patients with RRP can experience substantial impacts to daily living with decreased quality of life and high health care utilization. Based on an internal analysis of claims data and electronic health records, there are approximately 27,000 adult RRP patients in the US.

About PAPZIMEOS™ (zopapogene imadenovec-drba), for subcutaneous injection only
PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP and the first and only approved therapy to address the root cause of RRP. PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen comprising selected regions of human papillomavirus (HPV) types 6 and 11 proteins. PAPZIMEOS is designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with RRP. Discovered and designed in Precigen's labs using Precigen's proprietary AdenoVerse therapeutic platform, PAPZIMEOS represents a new therapeutic paradigm for RRP.

Indication and Important Safety Information

What is PAPZIMEOS?
PAPZIMEOS is a type of immunotherapy used to treat a condition called recurrent respiratory papillomatosis (RRP) in adults.

What is the most important information I should know about PAPZIMEOS?
Some people may have a reaction to the shot. Signs and symptoms may include redness, pain, swelling, itching, or warmth where the shot was given. After your first treatment, your healthcare provider will watch you for at least 30 minutes to make sure you're feeling okay.

Please contact your doctor immediately if you develop an infection, the reaction to your shot worsens, or you experience any of the below symptoms, which may indicate a systemic allergic reaction:

Difficulty breathing
Widespread rash
Facial swelling

Thrombotic events (blood clots that block your blood vessels) may occur after your PAPZIMEOS shot. Please notify your doctor immediately if you have the following symptoms:

Shortness of breath
Chest pain
Leg swelling
Persistent abdominal pain
Severe or persistent headaches
Blurred vision

What should I know before taking PAPZIMEOS?
Before taking PAPZIMEOS, tell your healthcare provider about all of your medical conditions, including:

If you are pregnant or plan to become pregnant because it is not known if PAPZIMEOS will harm the unborn baby.
If you are breastfeeding or plan to breastfeed. It is unknown if PAPZIMEOS is present in breast milk, or how it affects the breastfeeding child or milk production. Talk to your healthcare provider about the best way to feed your baby during treatment with PAPZIMEOS.

What are the most common side effects of PAPZIMEOS?
The most common side effects include:

Pain, redness, or swelling where the shot was given
Feeling tired
Chills
Fever
Muscle aches
Nausea (feeling sick)
Headache
Increased heart rate
Diarrhea
Vomiting
Sweating a lot

These are not all of the possible side effects of PAPZIMEOS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Precigen, Inc. at 1-855-PGE-NRRP (1-855-743-6777).

Please see full Prescribing Information .

Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Trademarks
Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
[email protected]

Media Contact:
Donelle M. Gregory
[email protected]

SOURCE Precigen, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (“Marex”; NASDAQ: MRX), the diversified global financial services platform, today announced that its Chief Executive Officer Ian Lowitt purchased 32,465 ordinary shares in Marex in the open market on Friday October 10, bringing his total holding to 2,615,016 ordinary shares. About Marex Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets.

, /PRNewswire/ -- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy" or the "Company"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced it plans to release its unaudited financial results for third quarter of 2025 ended September 30, 2025 before U.S. markets open on Monday, October 27, 2025.

The Company has scheduled a conference call to discuss the results at 8:00 AM U.S. Eastern Time on Monday, October 27, 2025 (8:00 PM Beijing / Hong Kong time on the same day).

The dial-in details for the earnings conference call are as follows:

Participant dial in (U.S. toll free): +1-888-346-8982

Participant international dial in: +1-412-902-4272

China mainland toll free: 4001-201203

Hong Kong toll free: 800-905945

Hong Kong local toll: +852-301-84992

Please dial in 10 minutes before the call is scheduled to begin and ask to join the Daqo New Energy Corp. call.

Webcast link:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=PBni7hsJ

A replay of the call will be available 1 hour after the conclusion of the conference call through November 3, 2025. The dial in details for the conference call replay are as follows:

U.S. toll free: +1-877-344-7529

International toll: +1-412-317-0088

Canada toll free: 855-669-9658

Replay access code: 9478610

To access the replay through an international dial-in number, please select the link below.

https://services.choruscall.com/ccforms/replay.html

Participants will be asked to provide their name and company name upon entering the call.

About Daqo New Energy Corp.

Daqo New Energy Corp. (NYSE: DQ) ("Daqo" or the "Company") is a leading manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2007, the Company manufactures and sells high-purity polysilicon to photovoltaic product manufacturers, who further process the polysilicon into ingots, wafers, cells and modules for solar power solutions. The Company has a total polysilicon nameplate capacity of 305,000 metric tons and is one of the world's lowest cost producers of high-purity polysilicon.

For more information, please visit www.dqsolar.com

SOURCE Daqo New Energy Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Also from this source

October 13, 2025 07:00 ET

 | Source:

BioXcel Therapeutics

NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough progress in addressing one of the most urgent unmet needs in psychiatry: the treatment of agitation associated with bipolar disorders and schizophrenia.

“It is a profound honor to ring the Nasdaq closing bell on behalf of the entire BioXcel team,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “This moment reflects not only how far we’ve come as an organization, but also our unwavering commitment to patients, families, and caregivers affected by mental illness. With the successful completion of our SERENITY At-Home pivotal trial, we are one step closer to our goal of redefining how agitation is managed and bringing IGALMI® directly to patients where they need it most: in the comfort and safety of their own homes.”

“Each milestone we achieve reinforces our belief that technology and compassion can converge to deliver meaningful change,” added Mehta. “As we celebrate this moment on the Nasdaq stage, we remain focused on our ultimate mission — to transform the standard of care in neuropsychiatry and improve lives around the world.”

The Nasdaq Closing Bell ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, beginning at 3:45 PM ET on October 14, 2025. The ceremony can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company’s planned advancement of its SERENITY program; redefining how agitation is managed; bringing IGALMI® directly to patients in the at-home setting; transforming neuroscience through the strategic use of AI-driven drug discovery and human insight; reimagining existing medicines and accelerating the development of innovative therapies; transforming the standard of care in neuropsychiatry and improve lives around the world; the ringing the Nasdaq closing bell. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI® or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI®; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contact Information

Corporate/Investors
Russo Partners
Nic Johnson
[email protected]
1.303.482.6405

Media
Russo Partners
David Schull
[email protected]
1.858.717.2310

October 13, 2025 07:00 ET

 | Source:

Forterra

Washington, D.C., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Washington, D.C., Oct. 13, 2025 — Forterra, the leader in autonomous mission systems today announced it has expanded its mission-ready autonomy solutions suite with four integrated modules, AutoDrive®, TerraLink, OASIS and Vektor. These modules are designed to transform logistics, mobility and interoperability to offer warfighters best-in-class autonomous systems solutions.

When it comes to fighting adversaries in the battlefield, precision, agility, speed and communications are all critical elements of maintaining a tactical advantage. Modern warfare runs on data, and today’s warfighters are facing more of it than any human can process fast enough to stay ahead. Each mission module within Forterra’s autonomy solutions suite can be independently integrated across a range of platforms, strengthening existing technologies. When used together, the four modules deliver a unified system that enhances situational awareness, reducing cognitive load and thereby helping Soldiers stay ahead of the fight.

AutoDrive®
AutoDrive® is an advanced autonomous driving system that enables reliable, real-time vehicle autonomy across complex, dynamic environments from battlefield operations to civilian logistics hubs. Originally designed for defense, this system-agnostic autonomy stack can be used in logistics and infrastructure applications as well, turning complex operations into coordinated, self-directed movement. It ingests and computes large amounts of data by combining advanced navigation and sensor technologies; this allows integrated vehicles to read the terrain and make decisions in real time.

TerraLink™
TerraLink is Forterra’s modular autonomous vehicle management platform, delivering robust command-and-control capabilities for seamless interoperability across diverse operational environments. It enables users and connected devices to work from the same live data picture, and it keeps critical information flowing in, even where conditions are unpredictable or bandwidth is limited.

Vektor™
Autonomy cannot exist without communications, and Vektor provides a secure, integrated communications network. Designed to integrate nearly any tactical waveform, Vektor is the secure communications hub for tactical units. It was developed to deliver high-bandwidth data flow and cross-waveform tranmissions in GPS-denied settings to ensure situational awareness when it matters most.

OASIS™
With its open interface system, OASIS standardizes hardware and software integration to allow sensors, effectors and payloads to be added and reconfigured as needed. This level of adaptability gives Forterra partners and customers the power to rapidly deploy new capabilities to maximize mission readiness.

Built with interoperability in mind, each module can be seamlessly integrated into any platform or system. Together, they create a scalable autonomy suite that allows Forterra’s customers to tailor their solutions.

“We developed these modules to operate as a cohesive autonomy system,” said Forterra CTO Joseph Putney. “Each of these modules strengthens a critical layer of the autonomy stack. Together, our customers get an end-to-end capability that can execute in real time so warfighters can focus on the mission and not the machinery.”

To learn more about these mission modules be sure to visit the Forterra booth (#6552) at AUSA 2025, or go to www.forterra.com.

Contact Info

Sanaz Tahernia
[email protected]
+1 240-631-0008

-

New advancement lays groundwork for quantum-enhanced modeling in carbon capture and molecular dynamics

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leading quantum company, today announced a significant advancement in quantum chemistry simulations, demonstrating the accurate computation of atomic-level forces with the quantum-classical auxiliary-field quantum Monte Carlo (QC-AFQMC) algorithm. This demonstration – in collaboration with a top Global 1000 automotive manufacturer – proved more accurate than those derived using classical methods and marks a milestone in applying quantum computing to complex chemical systems.

Computational chemistry techniques are used to predict forces arising from the atomic interactions and can be used to determine chemical reactivity. The ability to simulate atomic forces with extreme precision is critical for modeling materials that absorb carbon more efficiently. Accurate force calculations are essential for modeling how molecules behave and react, which is foundational to everything from drug discovery to decarbonization. With results shown by IonQ’s demonstration, quantum computing’s role in solving real-world chemistry problems has made meaningful progress.

Unlike previous research which focused on isolated energy calculations, IonQ’s implementation enabled the calculation of nuclear forces at critical points where big changes occur. These forces can be fed into classical computational chemistry workflows to trace reaction pathways, improving estimated rates of change within systems, and aiding in the design of more efficient carbon capture materials.

“This research demonstrates a clear path for quantum computing to enhance chemical simulations that are foundational to decarbonization technologies,” said Niccolo de Masi, Chairman and CEO at IonQ. “Our work goes beyond academic benchmarks. It demonstrates a practical capability that can be integrated into molecular dynamics workflows used across pharmaceuticals, battery, and chemical industries.”

Building on IonQ’s prior collaborations in computational chemistry, this advancement extends IonQ’s work with the QC-AFQMC algorithm, one of the methods that IonQ believes will deliver commercial advantage in the coming years, while adding another use case that deepens the company’s expertise and expands its quantum chemistry portfolio.

About IonQ

IonQ, Inc. [NYSE: IONQ] is a leading quantum company delivering solutions to solve the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking and sensing also position the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Fortune Future 50, Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the IonQ’s quantum computing capabilities and plans; IonQ’s technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ’s quantum computers; the necessity, effectiveness, and future impacts of IonQ’s offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ’s offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings; IonQ’s ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors; IonQ’s ability to sell effectively to government entities and large enterprises; changes in laws and regulations affecting IonQ’s and its suppliers’ businesses; IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ’s ability to effectively enter new markets; IonQ’s ability to deliver services and products within currently anticipated timelines; IonQ’s inability to attract and retain key personnel; IonQ’s inability to effectively integrate its acquisitions; IonQ’s customers deciding or declining to extend contracts into new phases; the inability of IonQ’s suppliers to deliver components that meet expectations timely; changes in U.S. government spending or policy that may affect IonQ’s customers; and risks associated with U.S. government sales, including availability of funding and provisions that allow the government to unilaterally terminate or modify contracts for convenience; changes in laws and regulations affecting IonQ’s patents; and IonQ’s ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

More News From IonQ, Inc.

Back to Newsroom

ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"), a world leader in spider silk technology*, is proud to announce the Company has succeeded in significantly increasing the production throughput of its recombinant spider silk production platform.

This increase is the successful result of the Company's continuous work in the selective breeding of parental strains for its production hybrid silkworms, which is the basis of its recombinant spider silk production system. Kraig's first successful hybrid, designated the BAM-1, demonstrated hybrid vigor, which increased both cocoon shell weight (a critical measure of silk output) and robustness. That hybrid was created by mating two genetically divergent parental strains. The fielding of the BAM-1 was a major improvement in spider silk production technology.

Over the past two years, Kraig Labs has used selective breeding to create more advanced parental strains with the goal of increasing hybrid vigor to further increase shell weight. One of these new advanced strains was specifically designed as a replacement for one of the original BAM-1 parental strains.

By mating the strongest of the BAM-1 parental strains with the new advanced strain, Kraig Labs has demonstrated measurable hybrid vigor (as measured by cocoon shell weight) of 22%, an increase in hybrid vigor of more than 245% compared to the BAM-1. The new advanced hybrid has been designated as BAM-1 Alpha and will be the Company's production workhorse moving forward.

"Our small team of researchers continues to outperform our competitors in spider silk R&D and commercial development. The creation of our new BAM-1 Alpha hybrid is the product of our focused vision for large-scale commercialization of spider silk and the dedication of our geneticists to that vision," said Kim Thompson, Founder and CEO of Kraig Labs. "Frankly, the 250% increase in hybrid vigor over the original BAM-1 has significantly exceeded our expectations and design parameters. The BAM-1 Alpha is producing larger cocoons and more silk, resulting in increased throughput and lower production cost. Though we do not have hard data yet on increases in robustness other than cocoon size and shell weight, our expectation is that general robustness will follow this same pattern."

Kraig Labs utilizes its proprietary genetically enhanced silkworm technology platform to produce recombinant spider silk. These silkworms spin recombinant spider silk fibers naturally within their cocoons, combining the scalability of traditional sericulture with the superior performance of spider silk proteins.

With BAM-1 Alpha now moving into commercial deployment, Kraig Labs will leverage its multi-facility production infrastructure to integrate this enhanced production hybrid into ongoing manufacturing. This advancement supports the Company's vision of delivering high-performance spider silk fibers for applications spanning performance textiles, defense, medical, and industrial markets.

This latest development underscores Kraig Labs' commitment to continuous innovation and its leadership in developing scalable bioengineered materials inspired by nature's toughest fibers.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
[email protected]

It’s not exactly a gold rush, but copper is quietly up about 27% in 2025. That’s not even close to the runup in gold or silver, but it’s still notable. The industrial metal is frequently referred to as “Dr. Copper” because the price of copper often predicts the health of the world’s economy.

That’s why copper has had volatile swings in the past 20 years. In the 2010s, copper’s fortunes were largely tied to infrastructure in China. However, in 2025, that story is being told on American soil. Support for copper prices comes from:

The AI revolution and the need for data centers and the electricity to power them

The need to upgrade the country’s existing electric grid

The ongoing demand for renewable energy solutions, including electric vehicles

That’s only a partial list, and although the focus is largely on the United States, there is a global case for copper.

But there’s also a supply issue. Chile and Peru are two of the leading sources of copper, but both countries have experienced supply disruptions. Furthermore, there aren’t enough significant new mining operations to keep up with the anticipated demand.

For investors, rising demand with supply constraints is a bullish sign that could mean the sector is at the beginning of a super cycle that could push the spot price of copper to $6 or higher for an extended period. Here are three basic materials stocks that are well-positioned for such a bull case.

Freeport-McMoRan: A Global Leader Facing Short-Term Disruption
Freeport-McMoRan Today

FCX

Freeport-McMoRan

$40.92 -2.40 (-5.53%)

As of 10/10/2025 03:59 PM Eastern

This is a fair market value price provided by Polygon.io. Learn more.

52-Week Range$27.66▼

$50.28Dividend Yield0.73%

P/E Ratio31.00

Price Target$46.56

Any discussion of copper stocks to buy must include Freeport-McMoRan Inc. NYSE: FCX. The company is one of the world’s largest publicly traded copper producers and supplies approximately 70% of all the domestically refined copper in the United States.

Although copper is its main source of mining revenue, Freeport-McMoRan also mines gold, which adds to its allure as gold demand is at record levels.

However, the company has faced significant disruption at some of its key operations in 2025 that has caused the company to scale back its full-year production estimates.

FCX stock is up just 13% in 2025, but it’s still trading about 6% below the analysts’ consensus price. But if recent upgrades accurately state the bull case, the consensus price may be far too low, which suggests that the stock could be part of a catch-up trade.

Southern Copper: Strong Gains, But a Valuation Reset May Loom
Southern Copper Today

$125.00 -5.57 (-4.27%)

As of 10/10/2025 03:59 PM Eastern

52-Week Range$74.84▼

$136.49Dividend Yield2.56%

P/E Ratio27.35

Price Target$109.88

Year-to-date growth is not a concern for Southern Copper Corporation NYSE: SCCO, one of the other large miners in this space. However, the stock is up 43% in 2025, and many analysts believe that a significant correction is overdue.

The bearish sentiment has to do with logistics more than copper fundamentals. With the current run-up, SCCO stock now trades around 29x earnings, a significant premium to its historical average of around 16x earnings.

The core issue comes down to the company’s operational footprint, which is mostly in Peru and Mexico, two countries that present significant regulatory concerns. The company’s production will be limited to these locations, which puts a ceiling on near-term growth.

The consensus price target for SCCO stock is around $109 per share. That would be a dip of around 15% from the stock’s closing price on October 9. However, an entry point in the stock would look more attractive at that price and with a lower valuation.

Global X Copper Miners ETF: A Diversified Play on the Metal Boom
Global X Copper Miners ETF Today

COPX

Global X Copper Miners ETF

$60.46 -3.52 (-5.50%)

As of 10/10/2025 04:10 PM Eastern

52-Week Range$30.77▼

$66.20Dividend Yield1.29%

Assets Under Management$3.36 billion

Many investors want exposure to mining and metals, but may not want to be stock pickers. That makes the Global X Copper Miners ETF NYSEARCA: COPX an attractive choice.

The name may be a little misleading. As of October, only about 17% of the fund’s holdings were dedicated to copper. That's likely a rotation play as 54% of the fund’s holdings are in precious metals. It also explains why the COPX fund is up more than 65% in 2025.

However, if copper follows the price of gold higher in the fall, the fund will have further to run.

In addition to its copper exposure, about 20% of the holdings are in diversified miners, such as Freeport-McMoRan and Southern Copper which are two of the fund’s top three holdings.

Should You Invest $1,000 in Global X Copper Miners ETF Right Now?Before you consider Global X Copper Miners ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global X Copper Miners ETF wasn't on the list.

While Global X Copper Miners ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report